このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Bausch Health Companies 将来の成長

Future 基準チェック /36

Bausch Health Companiesは、95.1%と2.7%でそれぞれ年率95.1%で利益と収益が成長すると予測される一方、EPSはgrowで104.1%年率。

主要情報

118.9%

収益成長率

125.5%

EPS成長率

Pharmaceuticals 収益成長	23.6%
収益成長率	2.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	19 Sep 2024

今後の成長に関する最新情報

Recent updates

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

業績と収益の成長予測

NYSE:BHC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	10,116	432	2,881	1,419	5
12/31/2025	9,787	377	1,940	1,494	8
12/31/2024	9,477	79	1,050	1,487	8
6/30/2024	9,202	-471	911	1,263	N/A
3/31/2024	8,966	-455	785	1,089	N/A
12/31/2023	8,757	-592	760	1,032	N/A
9/30/2023	8,542	-963	893	1,117	N/A
6/30/2023	8,350	-186	-665	-428	N/A
3/31/2023	8,150	-357	-773	-511	N/A
12/31/2022	8,124	-225	-996	-728	N/A
9/30/2022	8,127	254	-1,434	-1,179	N/A
6/30/2022	8,192	43	384	648	N/A
3/31/2022	8,325	-407	648	920	N/A
12/31/2021	8,434	-948	1,143	1,426	N/A
9/30/2021	8,451	-1,170	1,512	1,796	N/A
6/30/2021	8,478	-1,287	1,190	1,488	N/A
3/31/2021	8,042	-1,018	988	1,293	N/A
12/31/2020	8,027	-560	802	1,111	N/A
9/30/2020	8,038	-1,923	641	951	N/A
6/30/2020	8,109	-2,043	899	1,210	N/A
3/31/2020	8,597	-1,888	1,046	1,349	N/A
12/31/2019	8,601	-1,788	1,223	1,501	N/A
9/30/2019	8,498	-616	1,329	1,586	N/A
6/30/2019	8,425	-917	1,386	1,593	N/A
3/31/2019	8,401	-1,619	1,241	1,476	N/A
12/31/2018	8,380	-4,148	1,266	1,501	N/A
9/30/2018	8,422	-3,291	1,517	1,760	N/A
6/30/2018	8,505	-1,640	170	1,728	N/A
3/31/2018	8,610	-805	N/A	1,774	N/A
12/31/2017	8,724	2,404	N/A	2,290	N/A
9/30/2017	8,964	1,376	N/A	2,224	N/A
6/30/2017	9,224	-1,143	N/A	2,304	N/A
3/31/2017	9,411	-1,407	N/A	2,484	N/A
12/31/2016	9,674	-2,409	N/A	2,087	N/A
9/30/2016	10,024	-2,280	N/A	2,172	N/A
6/30/2016	10,332	-1,013	N/A	2,360	N/A
3/31/2016	10,644	-764	N/A	2,323	N/A
12/31/2015	10,442	-292	N/A	2,257	N/A
9/30/2015	9,906	596	N/A	2,476	N/A
6/30/2015	9,175	822	N/A	2,336	N/A
3/31/2015	8,484	1,001	N/A	2,302	N/A
12/31/2014	8,200	881	N/A	2,312	N/A
9/30/2014	8,043	502	N/A	1,759	N/A
6/30/2014	7,529	-746	N/A	1,342	N/A
3/31/2014	6,583	-861	N/A	1,271	N/A
12/31/2013	5,766	-866	N/A	1,042	N/A
9/30/2013	4,626	-1,079	N/A	830	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BHCは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: BHC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BHC今後 3 年以内に収益を上げることが予想されます。

収益対市場: BHCの収益 ( 2.7% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: BHCの収益 ( 2.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BHCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Bausch Health Companies 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target decreased by 18% to US$7.79

Price target decreased by 11% to US$8.36

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Price target decreased by 7.7% to US$9.56

Price target increased by 10% to US$10.33

Consensus EPS estimates fall from profit to US$0.03 loss

Recent updates

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Consensus EPS estimates increase from loss to US$0.11 profit

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

New major risk - Financial position

Consensus EPS estimates fall by 299%

Price target decreased by 29% to US$8.50

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Consensus EPS estimates upgraded to US$0.18 loss

Price target decreased by 8.9% to US$11.92

Consensus EPS estimates upgraded to US$0.33 loss

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Forecast breakeven date pushed back to 2025

CEO & Director exercised options to buy US$115k worth of stock.